Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company shows strong growth in monoclonal antibody revenues and PEMGARDA, with a solid cash position supporting its clinical trials. Despite competitive pressures and operational risks, management's confidence in their study outcomes and strategic public education efforts is promising. The Q&A revealed no major concerns, and the company's ability to adapt to evolving COVID trends is positive. The overall sentiment from the earnings call and Q&A indicates a positive outlook.
Key Financial Performance
Monoclonal antibody revenues Continued growth observed, while COVID vaccine utilization and revenue declined. The growth is attributed to overwhelming demand for antibody studies at the recruitment level, contrasting with declining demand for vaccines.
PEMGARDA revenue Grew 22% year-over-year compared to Q1 2025. The growth is attributed to the ongoing threat of SARS-CoV-2, which has periodic waves and is a ubiquitous threat, leading to more rational decisions by vulnerable populations and their care teams.
Clinical spend for DECLARATION trial Meaningful clinical spend observed in Q1 2026 to support the DECLARATION clinical trial. This is a substantial investment compared to ordinary clinical and SG&A spending, justified by its extraordinary commercial potential.
Cash position Remains strong, bolstered by additional cash raised in April through the at-the-market offering facility. This ensures financial stability despite increased spending on clinical trials and commercialization preparations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DECLARATION study: Upsized recruitment cohort for the study, resumed full-speed recruitment, and on track with previous estimates.
Virus neutralization: Confirmed neutralization of medicines against Omicron BA.3.2 variant.
Early discovery pipeline: Expanded pipeline includes measles, mumps, rubella, Lyme disease, and other pathogens for monoclonal antibody development.
Monoclonal antibody revenues: Continued growth in revenues while COVID vaccine utilization and revenue declined.
Direct-to-consumer efforts: Increased efforts generating greater disease and brand awareness.
Government affairs activity: Substantially increased activity to raise awareness among policymakers about the potential of their medicines.
AI platforms for healthcare provider engagement: Early efforts with AI tools to disseminate information to healthcare providers appear encouraging.
Focus on monoclonal antibodies: Positioned as a leader in monoclonal antibody development for infectious diseases, aiming to synergize with vaccination.
Public education initiatives: Launched 'antibodies for anybody' campaign to educate the public on the role of antibodies in immunology.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Policy Risks: The company is heavily involved in government affairs and regulatory activities, which could pose risks if policymakers or regulators do not align with the company's objectives or if regulatory hurdles arise.
Market Demand Challenges: While the company has seen strong demand for its monoclonal antibody studies, it noted that another company in the field abandoned a major vaccine study due to lack of demand, indicating potential market volatility.
Economic and Financial Risks: The company is making substantial investments in clinical trials and commercialization efforts, which could strain financial resources if expected returns are not realized.
Competitive Pressures: The company faces competition from other pharmaceutical companies, and its success depends on differentiating its products and maintaining market share.
Public Perception and Education: The company is investing in public education about monoclonal antibodies, but misinformation or lack of public understanding could hinder adoption and acceptance of its products.
Supply Chain and Operational Risks: The company is preparing for a new distribution model for its upcoming product, VYD2311, which could pose logistical and operational challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Recruitment for DECLARATION study: Recruitment for the DECLARATION study has resumed at full speed and is expected to finish imminently, keeping the program on schedule.
LIBERTY study: The LIBERTY study is expected to open and begin recruiting shortly to assess the safety and immunology of combining COVID-19 vaccines with monoclonal antibodies.
Monoclonal antibody VYD2311: The pivotal program for VYD2311 is well underway, with positive safety indicators from the Independent Data Monitoring Committee. The company anticipates high safety and tolerability for this product.
Future monoclonal antibody applications: The company is expanding its early discovery pipeline to include antibodies for measles, mumps, rubella, Lyme disease, and other pathogens, aiming to address unmet needs in infectious disease prevention and treatment.
Commercialization of VYD2311: Preparations are underway for the commercialization of VYD2311, leveraging existing infrastructure from the PEMGARDA business.
Direct-to-consumer and AI tools: The company is increasing its direct-to-consumer efforts and exploring AI tools to enhance the dissemination of information about its medicines to healthcare providers.
Financial outlook: The company expects a return to more normalized R&D spending after the completion of the VYD2311 pivotal trial and anticipates continued growth in PEMGARDA revenues.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you anticipate the 30-minute post-administration monitoring time for 2311 to be included in the label, and how might it impact adoption?
A:Management stated it is premature to determine if the 30-minute monitoring will be included in the label. They believe it is not a significant concern for adoption and uptake, as they expect high tolerability and low reactogenicity for the product. They anticipate that monitoring practices will evolve to resemble those for vaccines, with shorter waiting times as comfort increases.
Q:Do you see any indications of a new summer wave of COVID emerging based on wastewater monitoring?
A:Management noted that while wastewater monitoring shows some latency, COVID appears to have slowed its decline to low levels, which typically predicts a rise. They emphasized the importance of maximizing patient exposures before a potential rise and expressed confidence in their study setup for the summer.
Q:What point estimate or lower confidence bound would you consider clinically meaningful, commercially viable, and supportive of a BLA for DECLARATION?
A:Management emphasized that the determination of clinical meaningfulness and commercial viability depends on FDA standards and societal needs. They expect high efficacy (70%-90%) based on antiviral titers and aim to deliver a medicine with high protection and low tolerability penalties. They also highlighted the importance of safety and tolerability as primary goals of the DECLARATION study.
Q:How should we think about the single-dose versus multi-dose arms in the DECLARATION study?
A:The multi-dose cohort was included at the FDA's request to demonstrate safety. The monthly dosing interval was chosen to provide flexibility for future use. Management expects lower breakthrough infections in the multi-dose arm compared to the single-dose arm, consistent with their modeling. They remain confident in the study's progress and outcomes.
Q:What is the current surveillance time for vaccines, and have you observed any adverse events like anaphylaxis in the DECLARATION study?
A:Management stated they are unsure of the current vaccine surveillance time but believe it has become less stringent. They declined to comment on adverse events in the ongoing study to avoid potential errors but noted that previous related studies showed minimal safety concerns.
Q:Where is the current state of COVID surveillance, and could the antibody be used to respond to outbreaks?
A:Management stated that current surveillance, including wastewater monitoring, is sufficient to identify COVID trends. They envision using monoclonal antibodies rationally, based on data and attack rates, to allocate prophylactic medicine effectively during outbreaks. They believe this approach could significantly reduce the disease burden.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the current vaccine surveillance time and adverse events in the DECLARATION study, citing the need to maintain the integrity of the ongoing trial.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
COMPARE
COVID vaccine
Dr Mina
EVADE study
Lyme disease
MAHA movement
Mina Chief
Sanofi
Slide
adintrevimab
apple
burden
care provider
company
consumer
demand
disease benefit
disease medicine
education
establishment
experience
future
government affair
health care
host
immunization
immunology
implication
impression
manuscript
public
reactogenicity
recruitment
role
safety tolerability
speed
symptom
threat
tool
vaccinology
IVVD Transcript
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Positive5-14
The company shows strong growth in monoclonal antibody revenues and PEMGARDA, with a solid cash position supporting its clinical trials. Despite competitive pressures and operational risks, management's confidence in their study outcomes and strategic public education efforts is promising. The Q&A revealed no major concerns, and the company's ability to adapt to evolving COVID trends is positive. The overall sentiment from the earnings call and Q&A indicates a positive outlook.
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call summary reveals mixed signals: strong revenue growth and a solid cash position are positive, but uncertainties regarding trial resizing and market adoption challenges are concerning. The Q&A session highlights management's lack of clarity on critical details, which could undermine investor confidence. Despite promising financials, competitive pressures and public health risks persist, suggesting a neutral stock price movement in the near term.
Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mix of positive and negative factors. Strong revenue growth and capital raised are positives, but regulatory and clinical trial uncertainties, along with competitive pressures, pose significant risks. The Q&A section reveals management's vague responses on regulatory coordination, adding to uncertainties. While the company's market strategy for VYD2311 is ambitious, the absence of concrete guidance on overcoming regulatory hurdles tempers optimism. Given these mixed signals, the stock price is likely to remain stable, resulting in a neutral rating.
Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript
Unknown5-16
The earnings call presents a mixed picture. While there are positive elements such as reduced operating expenses, targeted profitability, and potential non-dilutive funding, there are significant challenges. Regulatory hurdles, competitive pressures, economic factors, and operational risks pose threats. The Q&A reveals management's lack of clarity on regulatory interactions and future plans. Despite some positive aspects, the absence of strong financial metrics or guidance and the challenges faced suggest a neutral stock price movement in the short term.
IVVD Slides
IVVD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
